
|Videos|May 3, 2017
Should IMRT Be the New Standard in Esophageal Cancer?
Author(s)Steven H. Lin, MD, PhD
This video discusses the use of intensity-modulated radiation therapy and whether it should be the new standard for treating patients with esophageal cancer.
Advertisement
Most esophageal cancer patients have distal tumors, resulting in vital organs such as the heart and lungs being exposed to substantial doses of radiation therapy.
In this video, Steven H. Lin, MD, PhD, of the University of Texas MD Anderson Cancer Center, discusses the use of intensity-modulated radiation therapy (IMRT) and whether it should be the new standard for treating patients with esophageal cancer.
IMRT is more advanced, but more costly, than standard 3D radiation.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
GLP-1 Receptor Agonists Show Modest Reduction in HR+ Breast Cancer Incidence
2
84 Exceptional Responders in De Novo Metastatic Breast Cancer (dnMBC) Drug Cessation in Patients With HER2-Positive Metastatic Breast Cancer; Multicenter Retrospective Study
3
BCMA CAR T-Cell Therapy Improves OS Vs Teclistamab in Multiple Myeloma
4
FDA Grants Priority Review to Giredestrant in ER+/HER2– Early Breast Cancer
5




































































